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AbstrACt
Introduction Invasive meningococcal disease is 
uncommon but associated with a high-case fatality rate. 
Carriage prevalence of the causative bacteria, Neisseria 
meningitidis, is high in adolescents. A large (n=34 500) 
cluster randomised controlled trial (RCT) to assess 
the impact of a meningococcal B (MenB) vaccine on 
meningococcal carriage was implemented in the state of 
South Australia (SA) for year 10, 11 and 12 senior school 
students in 2017–2018. This study will assess the impact 
of MenB vaccine (4CMenB) on carriage prevalence in 
school leavers in SA, 1 and 2 years after implementation 
of the cluster RCT in adolescents. Measuring the 
impact of population programmes on carriage can 
assist in informing future meningococcal immunisation 
programmes such as targeted age groups and use of 
catch-up campaigns.
Methods and analysis This repeat cross-sectional study 
will assess carriage prevalence in 2018 and 2019. All 
school leavers who attended year 12 in any school in SA in 
2018 or 2019 will be invited to participate in this study. An 
oropharyngeal swab will be taken from each participating 
student and a risk factor questionnaire completed by 
the student following informed consent. Students will 
attend clinics at SA universities, technical colleges, and 
metropolitan, rural and remote government council clinics. 
Confirmed vaccination history will allow a comparison in 
carriage prevalence between vaccinated and unvaccinated 
school leavers. A sample size of 4096 students per year 
will provide 80% power to detect a 20% difference in 
carriage prevalence of disease-causing meningococci 
(defined as genogroup A, B, C, W, X or Y) between years. 
Ethics and dissemination The study was approved 
by the Women’s and Children’s Health Network Human 
Research Ethics Committee. Results will be published 
in international peer review journals and presented at 
national and international conferences. 
trial registration number NCT03419533; Pre-results
IntroduCtIon
Neisseria meningitidis (meningococcus) is one 
of the most common causative organisms of 
bacterial meningitis in children and young 
adults1 and is associated with a substan-
tial burden of disease including long-term 
disability, with a case fatality rate of 5%–10%. 
N. meningitidis infection also causes signifi-
cant morbidity and mortality worldwide with 
approximately 500 000–1 200 000 cases and 
50 000–135 000 deaths reported annually.2 3 
N. meningitidis is classified into serogroups 
according to the biochemical composition of 
the capsular polysaccharide.2 4 The serogroup 
can be predicted by the detection of capsular 
biosynthesis genes which is interpreted as a 
corresponding genogroup. In this instance, 
strengths and limitations of this study
 ► This repeat cross-sectional study to assess carriage 
prevalence in adolescents 15–25 years of age who 
have completed school will provide the opportuni-
ty to assess carriage rates at the population level 
following introduction of a meningococcal B vaccine 
programme in younger adolescents who were vacci-
nated in a school programme (15–18 years of age).
 ► This study will be one of a limited number of studies 
that has confirmed participant vaccination history, 
and that will allow an accurate comparison in car-
riage prevalence between vaccinated and unvacci-
nated school leavers.
 ► Risk factors associated with oropharyngeal carriage 
will be adjusted for in the analysis; however, poten-
tial bias is inherent in observational cross-sectional 
study designs.
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genogroup refers to a meningococcus that has the genetics 
of a particular serogroup but does not necessarily express 
the capsule polysaccharide.5 The global distribution of 
meningococcal serogroups/genogroups is temporally and 
geographically dynamic. Clinically, invasive meningococcal 
disease (IMD) is most associated with isolates expressing 
serogroup A, B, C, W, X or Y.6 Serogroups B and C together 
account for a large majority of cases in Europe and the 
Americas, although serogroup Y emerged as a major 
contributor in the 1990s in North America.6 7 Serogroup A 
was responsible for the most recent epidemic in the sub-Sa-
haran meningitis belt in 2009 but is not the causative agent 
of epidemics elsewhere in the world. Following the intro-
duction of MenAfriVac the incidence of serogroup A-re-
lated IMD has dramatically reduced but has been replaced 
by an increasing burden of serogroup W and C IMD.6
From 2002 to 2015 the predominant meningococcal 
serogroup in Australia associated with IMD was serogroup 
B.8 Since 2013, serogroup W (MenW) and more recently 
serogroup Y (MenY) have emerged as significant causes 
of IMD although serogroup B remains the predominant 
serogroup in 2018 to date.9 In Australia, the incidence 
of IMD due to serogroup B is highest in children under 
1 year of age, followed by adolescents between the ages 
of 15 and 24 years.10 In South Australia’s (SA) popula-
tion of 1.7 million people,11 serogroup B has remained 
the predominant serogroup since national surveillance 
commenced in 1994.12
In 2017 in SA there were 36 IMD cases (22 due to sero-
group B, 11 serogroup W and 3 serogroup Y). Of these 
36 cases, 13 were in children aged <5 years (8 serogroup 
B, 4 serogroup W, 1 serogroup Y), one of whom died 
(serogroup B); there was 1 case in 5–9 year-olds and 1 
case in 10–14 year-olds (both due to group W), 4 cases 
in adolescents aged 15–19 years (4 serogroup B), 3 cases 
in 20–24 year-olds (2 serogroup B, 1 serogroup W) and 
14 cases (8 serogroup B, 4 serogroup W, 2 serogroup Y) 
and 2 deaths (1 serogroup B, 1 serogroup W) in adults 
25–78 years of age (A Koehler, Communicable Disease 
Control Branch, SA Health, personal communication, 18 
September 2018).
In 2017, 380 IMD cases were notified nationally with a 
notification rate of 1.5/100 000 compared with a notifi-
cation rate of 2.1/100 000 in SA. The proportion of IMD 
cases due to serogroup B is consistently highest in SA 
(60% in 2017), compared with 36% nationally.13
In 2017 the national notification rate for children <5 
years was 5.5/100 000 and 2.8/100 000 in adolescents 
15–19 years of age. From 2000 to 2017,13 notification 
rates of serogroup B-related IMD in South Australian 
15–19 year-olds ranged from 1.4/100 000 in 15 year-olds 
to a peak of 6.2/100 000 in 19 year-olds.14 The 19 years 
old age group often coincides with increased social and 
intimate contact involving activities such as finishing 
school and commencing higher education, employment 
or travelling.
IMD notification rates for Aboriginal and Torres 
Strait Islander people were over seven times the rate 
for non-Aboriginal people (9.3/100 000 compared 
with 1.3/100 000) in 2017, with disease due to sero-
group B being four times higher for Aboriginal people 
(2.0/100 000 compared with 0.5/100 000 nationally).8
Exposure to N. meningitidis is common in the popula-
tion, usually only leading to asymptomatic pharyngeal 
carriage. Although all IMD isolates possess a functional 
capsule synthesis locus, most carriage isolates are defined 
by the absence of the expression of the capsule, which 
is an essential virulence determinant for invasive disease. 
Carriage isolates are frequently acapsulate for one of 
three reasons: (1) absence of capsule genes (capsule 
null locus meningococci); (2) downregulation of capsule 
synthesis during carriage; and (3) mutational inactivation 
of capsule-encoding genes.15
Despite comprehensive population-based surveillance 
for IMD, data relating to carriage in Australia are scant 
and very little is known about overall carriage prevalence 
of N. meningitidis, or the proportion of strains that are sero-
group B. The only previous published Australian study 
reported 1.7% (3 MenY, the remainder were untypeable) 
carriage prevalence from a sample of 294 school-age chil-
dren of various ages in Queensland and was conducted in 
1989.16 A pilot study conducted in 421 South Australian 
first year university students in 2017 showed an overall 
carriage rate of 6.2% and carriage rate of IMD-associated 
meningococci of 5.3%.
Host age is one of the most important factors influ-
encing carriage, with peak carriage occurring at around 
18–19 years of age.17 Other factors that influence carriage 
include male gender, concomitant respiratory infections, 
active and passive smoking, number and closeness of 
social contacts and low socioeconomic status.18 19 The 
relationship between carriage and disease is not fully 
understood. With carriage rates significantly higher in 
adolescents, a reduction in carriage in this group has the 
potential to provide protection to unvaccinated people, 
including infants, through reduced transmission (herd 
immunity).
Two new vaccines, Bexsero 4CMenB (GSK) and 
Trumenba MenB-FHbp (Pfizer), which provide protection 
against meningococcal B (MenB) disease, are licensed in 
Australia but not funded through the National Immuni-
sation Program. There is currently limited evidence that 
4CMenB prevents carriage and no evidence for MenB-
FHbp. In the UK, a multicentre randomised controlled 
study was conducted to examine carriage in university 
students aged 18–24 years.20 Vaccination with 4CMenB 
resulted in significantly lower carriage of any meningo-
coccal strain (18.2%; 95% CI 3.4% to 30.8%) carriage 
reduction, and 26.6% (95% CI 10.5% to 39.9%) reduction 
in capsular groups BCWY. A significant carriage reduc-
tion for disease-associated sequence types of capsular B 
meningococci compared with controls was not observed 
(12.6%; 95% CI −15.9% to 34.1%).20 As these results are 
inconclusive, we sought to further assess the indirect 
(herd protection) effects of 4CMenB on acquisition of 
carriage by vaccinating senior school students in 2017 
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and 2018 as part of a cluster randomised controlled trial 
(RCT) in SA.21 Over 95% of schools in SA participated in 
the study and were randomised to vaccine (vaccination in 
2017) or control (vaccination in 2018) arms, with approx-
imately 70% of year 10, 62% of year 11 and 58% of year 
12 students (final school year) from participating schools 
consenting to the study.
Our proposed cross-sectional study will assess the 
impact of vaccinating over 30 000 senior school students 
in 2017–2018 on carriage prevalence in school leavers 
in SA at 1 and 2-year time points after implementation 
of the cluster randomised trial.21 Carriage prevalence in 
2018 will be compared with carriage prevalence in 2019. 
Overall effect will be estimated, taking account of the 
outcome for an average individual irrespective of vacci-
nation status rather than just the direct effect that was 
estimated in the RCT.
MEthods And AnAlysIs
study design
This is a repeat cross-sectional study to assess carriage 
prevalence in school leavers (first year after final year of 
senior school) in 2018 and 2019 after offering 4CMenB 
vaccination to senior school students in SA in 2017 and 
2018. Risk factors for carriage in school leavers will also 
be assessed. Individuals eligible to be enrolled into this 
study are South Australian school leavers between 17 and 
25 years of age in 2018 and 2019. There are no exclu-
sion criteria. School leavers who attended year 12 in 
any school in SA in 2017 will be invited to participate 
in 2018. Similarly, in 2019, school leavers who attended 
year 12 in any school in SA the preceding year (2018) 
will be approached to participate. An oropharyngeal swab 
will be taken from each participating student and a risk 
factor questionnaire completed by the student following 
informed consent. The questionnaire will collect infor-
mation on potential risk factors (prior meningococcal 
vaccination, smoking history, household size, recent 
antibiotic use, use of mouthwash, intimate kissing and 
socialising in pubs and clubs) for carriage of N. menin-
gitidis (online supplementary file). Vaccination will be 
confirmed in students who previously participated in the 
high school cluster randomised trial through the original 
study database. Participants who did not take part in the 
cluster randomised trial will be asked to provide consent 
to contact their immunisation provider to confirm vacci-
nation history. No ongoing visits are required. Partici-
pants will be offered a $40 voucher to compensate them 
for travel expenses.
Recruitment of study participants
School leavers will be invited to enrol in the study by 
advertising in the universities and technical colleges, and 
through council immunisation clinics in 2018. Students 
previously enrolled in the high school cluster randomised 
trial will be contacted directly and invited to participate 
in the study. We will recruit students from the three 
universities in SA: The University of Adelaide, University 
of South Australia and Flinders University and university 
colleges. Students will also be recruited from technical 
colleges and community immunisation clinics in metro-
politan, rural and remote areas of SA to ensure all school 
leavers in SA (n~19 000 per year) are approached and 
have an opportunity to participate.
At the end of each preceding year, a letter will be 
provided to schools to distribute to all students in their 
final year of school to invite them to participate. We aim 
to recruit 4096 school leavers each year from February to 
June in 2018 and 2019.
objectives
Primary objective
 ► Estimate the difference in carriage prevalence of 
disease-causing genogroups of N. meningitidis (A, B, C, 
W, X, Y) between South Australian school leavers in 
2018 (year 12 in 2017) and 2019 (year 12 in 2018), 
following implementation of a school immunisation 
programme (4CMenB vaccine) in year 10, 11 and 12 
South Australian students from 2017 to 2018.
Secondary objectives
 ► Estimate the difference in carriage prevalence of all 
N. meningitidis genogroups between South Australian 
school leavers in 2018 (year 12 in 2017) and 2019 
(year 12 in 2018).
 ► Estimate the carriage prevalence of each N. mening-
itidis genogroup (A, B, C, W, X, Y) in South Australian 
school leavers in 2018 (year 12 in 2017) and 2019 
(year 12 in 2018).
 ► Across years, estimate the difference in carriage prev-
alence of N. meningitidis genogroups causing disease 
(A, B, C, W, X, Y) between South Australian school 
leavers who received 4CMenB vaccine and unvacci-
nated students.
 ► Across years, estimate the difference in carriage preva-
lence of all N. meningitidis genogroups between South 
Australian school leavers who have received 4CMenB 
and unvaccinated students.
 ► Across years, estimate the carriage prevalence of each 
N. meningitidis genogroup (A, B, C, W, X, Y) in South 
Australian school leavers who received 4CMenB 
vaccine and unvaccinated students.
 ► Identify characteristics associated with carriage prev-
alence of all N. meningitidis genogroups in South 
Australian school leavers in 2018/2019.
 ► Identify characteristics associated with carriage prev-
alence of N. meningitidis genogroups causing disease 
(A, B, C, W, X, Y) in South Australian school leavers 
in 2018/2019.
Exploratory objectives
 ► Describe N. meningitidis carriage density for all geno-
groups in school leavers using qPCR.
 ► Describe genome sequencing of pathogenic N. menin-
gitidis (A, B, C, W, X, Y) in carriage among school 
leavers.
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study processes
Oropharyngeal swabs will be collected from all students 
following informed consent. Students will provide their 
own consent (parental consent is not required for 
17-year-old participants). A standard operating proce-
dure will be used to ensure consistent and optimal collec-
tion and handling of swabs. Auditing will occur at sites 
by randomised process and will be independent from the 
investigators and sponsor.
Specimen preparation, handling and storage
A 2 mL skim milk-tryptone-glucose-glycerol (STGG) 
medium will be used for collection of oropharyngeal 
swabs for both molecular and classical bacteriological 
culture methodologies. Once the samples reach the 
laboratory, details will be entered into the Laboratory 
Information System for recording, workup and subse-
quent reporting. All specimens will be subjected to DNA 
extraction using the Roche MagNa Pure extraction plat-
form for subsequent molecular testing using routine 
and standard protocols. Following DNA extraction 
the remaining STGG medium will be stored at −80°C. 
During transport from collection centres to the central 
laboratory, swabs will be kept cool using validated trans-
port methods for biological specimens. The majority of 
oropharyngeal swabs will be couriered to the laboratory 
for testing within 6 hours. All samples are expected to 
arrive within 16 hours of being taken, to minimise the loss 
of cultured isolates due to delayed freezing.22
Laboratory processes
All specimens will be subjected to PCR screening for the 
presence of specific meningococcal DNA (using porA 
gene detection) prior to being frozen. Further molec-
ular analysis will be used to determine which genogroup 
has been detected (A, B, C, W, X and Y). Any samples 
yielding a positive PCR will be cultured for Neisseria sp on 
selective agar (NIMM, Micro Neisseria Medium [VCTA], 
BioMerieux Australia), incubated in CO2 at 35°C. Plates 
will be examined daily for isolates for up to 72 hours. N. 
meningitidis will be identified by standard diagnostic labo-
ratory bacteriological methods using oxidase reaction 
and matrix-assisted laser desorption/ionisation time-of-
flight mass spectrometer. Whole genome sequencing and 
metagenomics will be conducted on cultured isolates, 
as described previously.22 From this will be determined 
serogroup, multilocus sequence type, porA and porB type. 
Quantitative PCR will be applied to the positive screen 
samples for estimation of the density of carriage of the 
Neisseria sp.23 A standard curve will be generated allowing 
comparison of crossing point values from the specimen 
analysis with the standard curve allowing the estimation 
of Neisseria density in the specimen.
The SA Pathology laboratories are accredited by 
National Association of Testing Authorities/Royal College 
of Pathologists of Australasia for routine testing of human 
and biological samples. All protocols are documented 
and reviewed regularly.
Data management
All data (consent forms, questionnaires and swab results) 
will be securely stored (password protected) on a data-
base held by The University of Adelaide. Range and 
logic checks will be performed on all data. All data will 
be deidentified prior to presentation or publication of 
results. The final data set will be held by Adelaide Health 
Technology Assessment, The University of Adelaide.
statistical analysis
Carriage prevalence of N. meningitidis genogroups 
as measured by PCR in school leavers is the primary 
endpoint for statistical analysis. Logistic regression with 
adjustment for confounding will be used to identify 
factors associated with carriage and to compare carriage 
rates annually and between vaccinated and unvacci-
nated students. Confounders will be identified separately 
for each outcome/comparison. Relationships will be 
described using ORs and 95% CIs.
All analyses will be undertaken according to a prespeci-
fied statistical analysis plan. All analyses will be performed 
using SAS V.9.4.
Sample size estimation
Assuming the carriage prevalence of disease-associated 
genogroups of N. meningitidis (A, B, C, W, X, Y) in school 
leavers in 2018 is 8%, a sample size of 4096 students per 
year will provide 80% power to detect a 20% relative 
reduction in carriage prevalence between 2018 and 2019 
(two-tailed alpha=0.05).24
Patient and public involvement
Study materials were reviewed by the Women’s and Chil-
dren’s Health Network Youth Advisory Group. A commu-
nications officer will work with school leavers including 
university students, students attending technical colleges 
and those in the workforce to establish appropriate and 
accessible avenues of communication. Involving students 
in the planning and delivery of communication strat-
egies is expected to facilitate two-way communication 
and provide opportunities for students to engage in 
research. Meningitis and meningococcal disease charities 
in Australia (Meningitis Centre Australia) and the UK 
(Meningitis Research Foundation) have been contacted 
and are aware of the proposed research and will assist in 
promoting awareness of the study to the public.
dIsCussIon
Evidence of indirect protection in addition to direct 
protection is an important consideration in implementa-
tion of meningococcal vaccine programmes. A carriage 
study of a cohort of school leavers in SA provides a unique 
opportunity to assess carriage prevalence at the popu-
lation level following introduction of an intervention 
in younger age groups (years 10, 11, 12) and compare 
carriage in individuals who have previously been vacci-
nated (in years 11 and 12) with individuals who are not 
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vaccinated. In SA, adolescents are generally 15 years of 
age during year 10 at school. This cross-sectional carriage 
study of school leavers is being undertaken in the age 
group with the highest rates of meningococcal carriage 
and invasive disease in SA. We will also assess any asso-
ciation between various known risk factors and history 
of 4CMenB vaccine on prevalence of nasopharyngeal 
carriage. Although MenC vaccines have shown impressive 
herd immunity effects, the new MenB vaccines are protein-
based vaccines and their impact on carriage and potential 
to confer herd protection remains inconclusive.20
The success of previously introduced meningococcal 
C vaccine programmes in the UK and Australia can be 
attributed to the combined efficacy of the vaccine against 
disease and carriage.19 Herd protection following intro-
duction of the MenC programme in the UK was deter-
mined as 67% after 1 year increasing to 75% after 2 years.25 
Experience with conjugate vaccines suggests protection 
is afforded by prevention of acquisition of carriage and 
transmission among the unvaccinated population and 
when infected, by the presence of antibodies at the time 
of infection.26–28
Evidence supporting a similar impact on carriage to that 
seen with the MenC vaccine programme is lacking, with 
inconsistent findings, even with other meningococcal 
conjugate vaccines. A cross-sectional study assessing the 
impact of MenACWY vaccine on carriage in a cohort of 
mostly vaccinated university students showed no signif-
icant effectiveness against carriage of MenW or MenY 
strains at least 5 months after vaccination; with continuing 
expansion of the 2013 strain of MenW continued in this 
population despite around 70% MenACWY vaccine 
coverage.29
In another study assessing the impact of CRM197-based 
conjugate vaccines MenACWY-CRM and 4CMenB on 
carriage, an impact on carriage was observed with the 
MenACWY-CRM vaccine on serogroups CWY, with signifi-
cantly lower carriage rates for serogroups CWY (36.2% 
[95% CI 15.6% to 51.7%] reduction) and, specifically, 
serogroup Y (39.0% [95% CI 17.3% to 55.0%] reduction) 
when assessed from 2 months after vaccination.20 These 
lower carriage rates are thought to result mostly from 
reduction in acquisition rather than increased carriage 
clearance in vaccinated individuals. Although 4CMenB 
did not result in a significant reduction in serogroup B 
carriage, there were significant differences in carriage of 
meningococci expressing genogroups BCWY and CWY, 
as well as genogroups CWY, capsular group Y and geno-
group Y from 3 months after vaccination with two doses.20
In healthy carriers, the diversity of genotypes is wide, 
with hypervirulent complexes carried rarely. Many hyper-
virulent strains are poor colonisers, including the ST-11 
complex, whereas the ST-23 complex is well adapted 
to a commensal relationship with the host.18 Our pilot 
study of pharyngeal carriage in university students 
showed no carriage of the hyperinvasive serogroup B 
strain harbouring the PorA 1.7, 2–4 variant which causes 
most cases of invasive disease in SA.22 It is not currently 
known what impact the introduction of protein-based, 
recombinant meningococcal vaccines will have on inter-
strain competition and carriage of non-disease-causing 
meningococci. Information on carriage in this group 
of adolescents, who only received a MenB vaccine, and 
not meningococcal ACWY vaccines, will also help under-
stand population effects of the MenB vaccine including 
any potential genotypic or phenotypic changes in genetic 
diversity or vaccine antigen expression during this period.
Carriage studies are important to improve our under-
standing of the population aspects of N. meningitidis. 
Measuring the impact of population programmes on 
carriage can assist in informing future modifications to 
programmes such as age groups to be targeted and use of 
catch-up campaigns
EthICs And dIssEMInAtIon
Results will be published in international peer review 
journals and presented at national and international 
conferences. The study findings will be provided in public 
forums and to study participants, participating schools 
and through social media. Results will also be reported 
in the commercial media including television, radio and 
print media. The protocol, informed consent forms, 
recruitment materials, social media and all participant 
materials have been reviewed and approved by the WCHN 
HREC and updated on  ClinicalTrials. gov: NCT03419533.
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